Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty

Orthopedics

Volumn 23, Issue 4, 2000, Pages 335-339

  Wade, William E ^a   Hawkins, David W ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b MERCER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DEEP VEIN THROMBOSIS; DOSE CALCULATION; HUMAN; LUNG EMBOLISM; OUTPATIENT CARE; POSTOPERATIVE COMPLICATION; PROPHYLAXIS; REVIEW; TOTAL HIP PROSTHESIS;

ADULT; AMBULATORY CARE; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; ENOXAPARIN; FEMALE; GEORGIA; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

EID: 0034000098     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Barnes CL, Nelson CL, Nix ML, McCowan TC, Lavender RL, Barnes RW. Duplex scanning versus venography as a screening examination in total hip arthroplasty patients. Clin Orthop. 1991; 271:180-189.
2. Giachino A. Relationship between deep vein thrombosis in the calf and fatal pulmonary embolism. Can J Surg. 1988; 31:129-130.
3. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med. 1981; 94:439-444.
4. Sikorski JM, Hampson WG, Staddon GE. The natural history and etiology of deep vein thrombosis after total hip replacement. J Bone Joint Surg Br. 1981; 63:171-177.
5. Silver D. An overview of venous thromboembolism prophylaxis. Am J Surg. 1991; 61:537-540.
6. Clagett CP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest. 1995; 108:3125-3345.
7. Johnson R, Green JR, Charnley J. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement. Clin Orthop. 1977; 127:123-132.
8. Fredin HO, Nillius AS. Fatal pulmonary embolism after total hip replacement. Acta Orthop Scand. 1982; 53:407-411.
9. Trowbridge A, Boese CK, Woodruff B, Brindley HH Sr, Lowry WE, Spiro TE. Incidence of posthospitalization proximal deep venous thrombosis after total hip arthroplasty: a pilot study. Clin Orthop. 1994; 299:203-208.
10. Seagroatt V, Tan HS, Goldacre M, Bulstrode C, Nugent I, Gill L. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. Br Med J. 1991; 303:1431-1442.
11. Sikorski JM, Hampson WG, Staddon GE. The natural history and aetiology of deep vein thrombosis after total hip replacement. J Bone Joint Surg Br. 1981; 63:171-177.
12. Eisneberg JM. Clinical economics: a guide to the economic analysis of clinical practices. JAMA. 1989; 20:2879-2886.
13. Lee J, McLaughlin-Miley C, Chatteron ML. Cost-effectiveness analysis. In: Bungay KM, Osterhaus JT, Paladino JA, Sanchez LA, eds. Pharmacoeconomics and Outcomes: Applications for Patient Care Module 2. Kansas City, Mo: American College of Clinical Pharmacy; 1996:171-193.
14. Cardinale V, ed. Red Book. Montvale, NJ: Medical Economics Co Inc; 1997.
15. Menzin J, Colditz G, Regan M, Richner R, Oster G. Cost-effectiveness of enoxaparin versus low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med. 1995; 155:757-764.
16. Mamdani MM, Weingarten CM, Stevenson JG. Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: decision and cost-effectiveness analysis. Pharmacotherapy, 1996; 16:1111-1127
17. Armstrong EP. Sensitivity analysis. In: Bungay KM, Osterhaus JT, Paladino JA, Sanchez LA, eds. Pharmacoeconomics and Outcomes: Applications for Patient Care Module 2. Kansas City, Mo: American College of Clinical Pharmacy; 1996:171-193.
18. Planes A, Vochelle N, Darmon J, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996; 348:224-228.
19. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996; 335:696-700.
20. Wilson MG, Pei LF, Malone KM, Polak JF, Creager MA, Goldhaber SZ. Fixed low-dose versus adjusted higher-dose warfarin following orthopedic surgery: a randomized prospective trial. J Arthroplasty. 1994; 9:127-130.
21. Nilsson PE, Bergqvist D, Benoni G, et al. The post-discharge prophylactic management of the orthopedic patient with low-molecular-weight heparin: enoxaparin. Orthopedics. 1997; 20(suppl):22-25.
22. Planes A, Vochelle N. The post-hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics. 1997; 20(suppl):18-21.
23. Pedersen OM, Aslaksen A, Vik-Mo H, et al. Compression ultrasonography in hospitalized patients with suspected deep venous thrombosis. Arch Intern Med. 1991; 151:2217-2220.
24. Heijboer H, Cogo A, Buller HR, et al. Detection of deep vein thrombosis with impedance plethysmography and real-time compression ultrasonography in hospitalized patients. Arch Intern Med. 1992; 152:1901-1903.
25. Wells PS, Lensing AWA, Davidson BL, Prins MH, Hirsh J. Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery: a meta-analysis. Ann Intern Med. 1995; 122:47-53.